Intermittent administration of PTH has been found to be an effective anabolic agent in cancellous bone. We have reported previously that combined treatment with PTH and estrogen in estrogen-deficient rats was beneficial in correcting established osteopenia. To determine if the beneficial effects of PTH therapy can be preserved by estrogen alone and whether PTH therapy can be effective in treating osteopenic subjects stabilized with estrogen, we have undertaken a "crossover" study in the rat model of estrogendeficiency induced osteopenia. Six-month-old female rats were ovariectomized and after 5 wk treated for 8 wk with vehicle, 30 rig/kg per day of rPTH(1-34) plus 15 ,.g/kg per day of 17fi-estradiol or 17f3-estradiol alone. One group from each treatment regimen was then sacrificed and for an additional 8 weeks the remaining rats were (a) maintained on their previous treatment; (b) "crossed over" to their reciprocal treatment; or (c) administered vehicle only. At the end of this second 8-wk treatment period all rats were sacrificed. Bone mineral density of the distal femur, histomorphometric measurements of the proximal tibia and mechanical testing of the distal femur and selected vertebral bodies were performed. Our results demonstrated that (a) the gains in bone mass, trabecular connectivity and mechanical strength induced by PTH can be maintained by estrogen alone, but are reversed when both agents are withdrawn; and (b) rats with established osteopenia, maintained on estrogen treatment alone, can derive the full beneficial effects from the addition of PTH to the treatment at a later date. These data indicate that combined and/or sequential use of antiresorptive and anabolic agents may be a promising approach to the treatment of osteoporosis. (J. Clin. Invest. 1995. 96:2331-2338
Introduction
Antiresorptive agents have long been used successfully to prevent bone loss associated with postmenopausal osteoporosis. However, these agents have not been able to restore lost bone mass or microarchitecture (1) . The search for an anabolic agent that is capable of reversing this bone loss has received substantial attention in recent years. Several agents, such as fluoride (2, 3) , intermittent PTH in humans (4) (5) (6) (7) and in rats (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , PGE2 (21) (22) (23) (24) , nandrolone decanoate (25) , TGF-b2 (26) (27) , and IGF-1 (28) (29) (30) (31) (32) (33) (34) in rats, have shown promise to fulfill such a role. We (19, 35) , and others (15) (16) (17) , have recently shown that a treatment regimen combining antiresorptive and anabolic agents can halt further cancellous bone loss and restore some of the lost bone mass and structure, whether given in a preventive or curative mode. Long-term parenteral administration of an anabolic agent can be inconvenient, as well as a source of discomfort for the patient and thus results in reduced compliance. In long term usage, there also exist the possible problems of toxicity, loss of effectiveness, and economic considerations. Studies in rats have demonstrated a rapid disappearance of newly acquired bone when the anabolic agent is withdrawn and, therefore, continuous administration was needed to preserve the gain (36, 37) . Jee and colleagues have proposed the use of an antiresorptive agent to maintain newly gained bone mass, induced by PGE2, in rats (23, 24) . Since PTH has been used successfully in both humans (4) (5) (6) (7) and rats (8, 9, 11, 13, 14, 18) to restore lost bone mass, we decided to examine whether the newly gained bone can be preserved by estrogen therapy alone.
In animal studies, PTH has been used to treat estrogen deficient rats by itself or concomitent with antiresorptive agents. This is somewhat different from the patients who are treated at osteoporosis clinics as many of them are often on hormone replacement therapy already. In the present study, we undertook an investigation to determine if the benefical effects of PTH can be realized after prolonged use Bone mineral density. Bone mineral density of c measured by dual energy x-ray absorptiometry (Q Waltham, MA) under 5 cm of 70% alcohol with a 0. at high resolution mode. 25% of the femur, as meast end, which is rich in cancellous bone was analyzed. nations of five different femurs, with a new placeme each determination, showed a coefficient of variatic Osteocalcin and pyridinoline assays. The rat sen centration was measured with a commercial radioimr medical Technologies Inc., Stoughton, MA) using standard and a region specific domain of goat anti-x body. Urinary pyridinoline and creatinine were mea kit from Metra Biosystems (Palo Alto, CA). Intra-a variation for rat osteocalcin and pyridinoline were tively.
Histomorphometry and trabecular strut analysis.
were dehydrated, embedded undecalcified in methy sectioned longitudinally using a Jung Ultracut mix Jung, Heidelberg, Germany Table I ). 6 and 12%, respec-The gain in cancellous bone volume was significant for the first 8 wk of treatment (group 8) but further treatment with the Excised right tibias combination of PTH and estrogen (group 9) did not result in yl methacrylate and any additional increments in Cn-BV/TV or parameters of concrotome (Reichertnectivity but did seem to increase the BMD of the distal femur e tibias, 4-mm non-(Figs. 2-3, Table I ). Th.Th increased in rats treated with PTH stained by the Gold- (Table I) but was unaffected by estrogen depletion (groups 5-n-BV/TV), trabec-7). With the combined PTH and estrogen treatment (groups Th) were measured 8-9), Tb.N and the parameters of connectivity (N.Nd, N.Nd/ iring system (Opto-N.Tm) were increased and disconnectivity parameters (Th.Sp ved on a teievision and Tm.Tm/TSL) were decreased, when compared with vehicle from each section, treated Ovx rats (groups 5-7) (data not shown). This change Ito the lowest point was also seen in BMD measurements of the distal femur, a nts. Each field was cancellous-rich region of the femur (Fig. 4 drawal of both PTH and estrogen after 8 wk of treatment (group 11 ) resulted in significant decreases in bone mass and structure, whereas, maintaining treated animals on estrogen alone (group 10) protected the gains in bone mass and structure, when compared with a similarly treated group (group 8) before withdrawal.
PTH treatment can be used as an anabolic agent after bone loss has been previously stabilized by estrogen. In rats with established estrogen deficiency-induced bone loss, as expected, estrogen treatment was effective in preventing further bone loss (groups 12, 14 vs. group 5). These rats retained their Cn-BV/ TV, connectivity parameters (Nd.Nd) and bone mass in cancellous-rich regions of bone, when compared to their bone status at the initiation of treatment (group 5, Fig. 2-3 , Table I ). When PTH and estrogen were co-administered to Ovx rats with established osteopenia, after stabilization with estrogen for 8 wk (group 13), the combined treatment restored bone mass and structural parameters to the level of age-matched, Shamoperated animals (group 4) (Fig. 2-3 , Table I ).
Biochemical markers of bone turnover; osteocalcin and pyridinoline. Biochemical markers of turnover, osteocalcin and pyridinoline, showed an age-related decrease in Sham-operated animals (groups [1] [2] [3] [4] (Table H) . Osteocalcin and pyridinoline levels returned to the elevated levels seen in untreated Ovx rats (group 7) in rats in which both PTH and estrogen treatment were withdrawn (group 11). The addition of PTH to the estrogen treatment resulted in a moderately higher level of osteocalcin than estrogen treatment alone, but the difference was not significant.
Mechanical strength is related to cancellous bone volume and connectivity parameters. In all groups sacrificed at week 21, mechanical strength of the cancellous bone-rich distal femur, cortical bone-rich femoral diaphysis and vertebral bodies were 5.E 17".. OT Figure 3 . Effects of combined PTH plus estradiol and crossover treatments on node to node strut length at the proximal tibia. Numbered points represent group numbers. The sample variations are reported in Table I. examined. This time period was employed in order to allow for significant bone loss in the vertebral bodies, as determined by Wronski et al. (45) . Mechanical strength of the distal femur, using an indentation test that applied force directly into the marrow cavity, correlated with the BMD of the distal femur (initial max. load: r = 0.60, P < 0.01; stiffness: r = 0.32, P < 0.05) and the proximal tibial Cn-BV/TV (initial max. load: r = 0.63, P < 0.01 ) but not with the diaphyseal femur BMD (initial max. load: r = 0.25, NS; stiffness: r = 0.26, NS). The compressive strength of the vertebral bodies showed similar results in that it correlated with the BMD of the distal femur (peak load: r = 0.59, P < 0.01; stiffness: r = 0.58, P < 0.01 ) but not with the BMD of the diaphyseal femur (peak load: r -0.37, NS; stiffness: r = 0.49, P < 0.05). Thus, among cancellous-rich bones, the changes in the BMD and cancellous bone volume were proportionally reflected by the changes in the mechanical strength (Table III) . The stiffness measurements from each group were similar to the load measurements. when the bone mass has returned to a point where fracture risk that the newly gained bone mass would be lost if the treatment is substantially reduced or where treatment has to be disconwas not continued (35, 36, 46) . The idea of using an antitinued for any reason, we have studied the efficacy of using resorptive agent to preserve the bone gained from the use of estrogen alone to maintain the increased bone mass. In the anabolic agents has only recently been proposed. Jee and his present study, we have employed an animal model of postmenocolleagues demonstrated that one can preserve PGE2-induced pausal osteoporosis in a "crossover" study to determine bone gain by administering risedronate (23, 24) . Physical exerwhether estrogen treatment alone can maintain improvements cise (46) and pamidronate (47) were shown to maintain PTHin bone mass and microarchitecture and whether this anabolic stimulated increases in bone mass in ovariectomized rats after It is shown at statistical significant with P value set at 0.05 in the Duncan's multiple range test of the ANOVA. a, P < 0.05 for Cn-BV/TV; b, P < 0.05 for Th.Th; c, P < 0.05 for Nd.Nd; d, P < 0.05 for BMD at distal femur. (38) .
istered (15) . The implication of these findings is that combined The question of whether the anabolic effects of PTH plateau PTH and estrogen treatment could result in more rapid anabolic It is shown as statistical significant with P value set at 0.05 in the Duncan's multiple range test of the ANOVA. a, P < 0.05 for Init. max.
load in the indentation test in the marrow cavity of distal femur; b, P < 0.05 for Stiffness in the indentation test in the marrow cavity of distal femur; c, P < 0.05 for Load in compression test of vertebral body; d, P < 0.05 for Stiffness in compression test of vertebral body. throughout 15 wk of treatment similarly regardless if the rats were treated with PTH alone or with PTH plus estrogen. (17) . This may be the reason why we observed a small increase in the BMD at the distal femur between 8 and 16 wk of PTH plus estrogen treatment. A small increase of BMD was also found when estrogen was given during weeks 5-13 in Ovx rats or weeks 13-2 1 in rats previously treated with PTH plus estrogen. This could result from a transient reduction in the number of resorption cavities in Ovx rats and, possibly the continued anabolic action of PTH on cortical bone in PTH plus estrogen treated rats. One should also be aware that the complicated effects of estrogen-induced changes in cortical dimensions, such as expansion of the marrow cavity and periosteal surface, may affect the BMD measurements as well. Further studies will be needed to address the changes which occurred in cortical bone.
Bone mass has often been used as a surrogate to evaluate bone fragility. However, a direct method of testing the mechanical strength of the bone could provide more relevant information about its structural integrity (48) . Bone strength is influenced by many factors, amongst them the content of organic and mineral phases and the internal architecture of the bone. The architecture of cancellous bone may be a particularly important contributor to its mechanical strength and this feature cannot be adequately addressed by bone mass measurements alone. We performed a series of mechanical testing techniques that were designed to be particularly indicative of the structural integrity in both axial (vertebral body) and appendicular (distal femur) bones. The high correlation between BMD, Cn-BV/TV and mechanical strength indicates that these determinants of bone mass can be a suitable surrogate for mechanical strength in this model. The high correlation between connectivity and disconnectivity parameters and mechanical strength also suggests that changes in the integrity of the trabecular lattice strongly influence the ability to support mechanical load. Though better studied in humans (49, 50) , the validity of the relationship between cancellous-rich rat vertebral bone compressive strength and density in rats has been observed in group ( 15, 51 ) and individual (52) comparisons. Using an indentation test similar to the one employed in the present study, Martin (53) showed comparable changes in ash mass and penetration strength between control and experimental groups of rats at the distal femur and the proximal tibia. Thus, both methods of measuring cancellous bone strength are appropriate for future experimentation in rats.
Biochemical markers, such as osteocalcin and pyridinoline, have been used extensively in the study of bone turnover. Using a rat specific osteocalcin radioimmunoassay and ELISA measurements of urinary pyridinoline, we showed that there was an age-related decrease in the level of these two markers. Estrogen deficiency, as a result of ovariectomy, significantly increased the level of both markers but the age-related decline was still evident in the estrogen deficient animals. Estrogen administration reversed the increase in turnover markers seen in ovariectomized animals and the markers rose again when estrogen was withdrawn. These results are very similar to the findings in human studies after oophorectomy (54) where biochemical bone turnover markers were elevated immediately after surgery and the elevation of these markers was abated after the initiation of estrogen replacement therapy. Osteocalcin, a bone formation marker, was found to be higher, although not significantly, in each of our PTH plus estrogen treated groups. The lack of statistical significance in these comparisons could result from (a) the lack of sufficient sample size, (b) insufficient sensitivity of the assay or, (c) the percentage of osteocalcin released from osteoblasts into the circulation may be altered as a result of PTH administration so that more osteocalcin molecules were deposited into the newly formed bone. A different method of study will be needed to address these issues. In addition, one cannot rule out the possible influences on the markers of longitudinal or radial bone growth, as the skeletons of these animals were still growing, albeit, very slowly. There are still questions which need to be answered before the anabolic action of PTH can be applied as a clinical tool. The use of animal models can provide a screening process to determine the effectiveness of these approaches. In this study, we have provided experimental data in support of the feasibility of using estrogen, an anti-resorptive agent, to preserve the bone gained by PTH treatment as well as the successful initiation of anabolic treatment after bone loss has been stabilized by estrogen. With further refinement, this type of sequential treatment with anti-resorptive and anabolic agents could be a promising approach for the future treatment of postmenopausal osteoporosis.
